Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Investor Presentation
AKUMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Akums Drugs reported Q1 FY26 total income of ₹1,051 Cr, up 2.4% YoY. Adjusted EBITDA rose to ₹156 Cr with margin improving 208 basis points YoY to 14.8%, while adjusted PAT grew 57 bps YoY to 6.2% at ₹65 Cr. The company received €100 Mn as advance against a European CDMO contract, boosting cash surplus to ₹1,518 Cr (from ₹566 Cr in FY25). Key milestones include first EU dossier approval for Rivaroxaban, first dossier filing in Switzerland, and crossing 1,000 cumulative DCGI approvals. Commercial EU supplies are set to begin April 2027. Management noted continued weakness in API pricing and muted domestic volume growth (below 0.5%), but highlighted improved gross margins from a better product mix and strategic focus on CDMO leadership.
Margin expansion and a strong cash position (₹1,518 Cr) give Akums flexibility for both organic and inorganic growth, which is positive for long-term shareholders. However, tepid revenue growth and ongoing API pricing pressure may limit near-term upside, so investors should watch for sustained volume recovery and progress on EU contract commercialization.